ANG Lifesciences Quarterly Results for Trading Insights
In Mar 2026, ANG Lifesciences (ANG) reported revenue ₹24 Cr and net profit ₹-1 Cr — revenue +33.3% YoY. For annual financials, live price and key ratios, visit ANG Lifesciences share price today.
ANG Quarterly Results — Revenue, Profit & EPS Highlights
ANG Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse ANG complete financial statements for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹24 Cr in Mar 2026 (-7.7% vs Sept 2025, +33.3% vs Mar 2025)
- Net Profit of ₹-1 Cr in Mar 2026 (+66.7% vs Sept 2025, +50.0% vs Mar 2025)
- EBITDA of ₹3 Cr in Mar 2026
- Operating Margin of 11.0% in Mar 2026
- Earnings Per Share of ₹-1.07 in Mar 2026 (+52.2% vs Sept 2025)
ANG Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ANG quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 24 | 26 | 18 | 25 | 19 | -7.7% | 33.3% |
| Net Profit (₹ Cr) | -1 | -3 | -2 | -2 | -5 | - | - |
| EBITDA (₹ Cr) | 3 | 0 | 0 | 1 | -3 | - | - |
| EPS (₹) | -1.07 | -2.24 | -1.56 | -1.52 | -3.60 | - | - |
| Operating Margin (%) | 11.0% | 0.0% | -4.0% | 3.0% | -14.0% | - | - |
ANG Share Price Trend — 1-Year Movement Across Quarterly Results
ANG Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore ANG share price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ANG vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
ANG Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1140.6 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.2 |
All amounts in ₹ Crores